Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy
Although randomized controlled trials (RCTs) provide evidence of efficacy, generalization of
these results to patients in the real-world setting is challenging, given RCTs are conducted
in highly selected patient populations.
An understanding of the effectiveness and safety of approved cancer therapies in routine
clinical practice is essential in order to optimize the management of these patients and to
identify treatment and safety gaps.
This is the first Canadian study to describe real-world treatment patterns/sequencing,
effectiveness and safety for postmenopausal HR+ HER2- advanced breast cancer patients. This
registry incorporates an observational prospective cohort design and will enroll 320
postmenopausal HR+ HER2- advanced breast cancer women that have been previously exposed to
non-steroidal aromatase inhibitor (NSAI) therapy being treated with endocrine therapy (ET)
or ET in combination with targeted therapy (TT).
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society